Hara H, et al. - Including 5 years follow-up, this prospective Phase 2 study in 20 patients is planned to test gemcitabine and docetaxel (GD) combination with respect to efficacy and toxicity in patients with advanced bone sarcomas and soft tissue sarcomas. The treatment regimen will be gemcitabine 900 mg/m² on Days 1 and 8, and docetaxel 70 mg/m² on Day 8 in 3-week cycles until disease progression or other proof of treatment failure. Researchers will determine how progression-free survival would be influenced by GD (primary aim) as well as they will assess response rate, tumour control rate, overall survival, and adverse event rate (secondary objectives). They assume that this combination would serve as second, third, or later line treatment for patients with sarcomas (particularly bone sarcomas) only if it proves to be acceptable.